Free tool
Rare disease stocks
We cover 7 companies grouped under the Rare disease theme. The median market value in the group is $22.99M. Across the group, the median move over the past trading day is +2.97%. Price change over the past year runs from −39.8% to +3598.3% across the middle 80 percent of the group, with a median of −7.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| PAR.AX | Paradigm Biopharmaceuticals Limited | $96.60M | Micro cap | −22.41% |
| 0IIM.L | Esperion Therapeutics, Inc. | $61.56M | Micro cap | +46.64% |
| NSRX | Nasus Pharma Ltd. | $48.01M | Micro cap | −48.69% |
| 4884.T | Kringle Pharma, Inc. | $22.99M | Micro cap | −7.41% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8687.69% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −33.91% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +205.34% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.